Science

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer

Mark M. Awad/mskcc.org

Jan 15, 2025, 15:32

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer

Dipesh Uprety, Assistant Professor of Thoracic Oncology at the Barbara Ann Karmanos Cancer Institute, shared an article by Mark M. Awad on X:

“Phase III CheckMate-816 Journal of Clinical Oncology Neoadjuvant Nivo + Ipi vs Chemo:-

Md EFS 54.8 mo vs 20.4 mo.
pCR 20.4 vs 4.6 MPR 28.3 vs 14.8%.
pCR or MPR had higher baseline 4-gene inflammatory scores than those without in IO arm.”

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.

Authors: Mark M. Awad, et al.

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer

Dipesh Uprety, Assistant Professor of Thoracic Oncology at the Barbara Ann Karmanos Cancer Institute, specializes in treating lung cancer, mesothelioma, thymoma, and thymic carcinoma. He also serves as the Editor-in-Chief of The Cancer News, an authoritative resource on cancer-related topics.

Barbara Ann Karmanos Cancer Institute cancer chemotherapy clinical oncology Dipesh Uprety fight against cancer Global fight against cancer ipilimumab Lung cancer Mark M. Awad neoadjuvant nivolumab OncoDaily Oncology

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology

Leo Messi, Richard Gere and Alejandra, Princess Dina and Paco Arango join the Global OncoThon to support childhood cancer research